Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen

Eliezer Katz; Toby P. Coates; John S. Gill; Jean Tchervenkov; Steven Paraskevas; Paul Harden; Vanessa-Giselle Peschard; Marcela Laurito; Steven Perrin

doi:10.1016/j.ajt.2025.12.191

Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen

American Journal of Transplantation 2026

View at publisher

Authors: Eliezer Katz, Toby P. Coates, John S. Gill, Jean Tchervenkov, Steven Paraskevas, Paul Harden, Vanessa-Giselle Peschard, Marcela Laurito, Steven Perrin

DOI: 10.1016/j.ajt.2025.12.191

Cited by: 0

Fields of Study & Subjects

Renal Transplantation Outcomes and Treatments Transplantation: Methods and Outcomes Organ and Tissue Transplantation Research

Publication details

Journal / source: American Journal of Transplantation
Volume: 26
Issue: 1
Pages: S88–S88
Publication date: 1 January 2026
Language: EN